MannKind completes randomization in phase 1b study for IPF treatment

June 3, 2026 6:05 AM

MannKind Corporation (NASDAQ: MNKD) announced completion of patient randomization in its Phase 1b INFLO-1 clinical trial and enrollment of the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found